We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
8 own
7 watching
Current Price
$28.31
$-1.33
(-4.49%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
4,423.26M
52-Week High
41.46
52-Week Low
19.86
Average Volume
0.59M
Dividend Yield
--
P/E Ratio
-0.12087912
Market Capitalization4,423.26M
52-Week High41.46
52-Week Low19.86
Average Volume0.59M
Dividend Yield--
P/E Ratio-0.12087912
What does the Stockal+Disclaimer.pdf do?
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company s products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
7days ago
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE Get Rating) has earned a consensus recommendation of Moderate Buy from the ten analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and eight have issued a ...
Globe Newswire
25days ago
CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences. Event:...
Benzinga
28days ago
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 6.42% to $25.37 during Tuesday's session after the company reported worse-than-expected third-quarterEPS results and filed for a mixed-securities shelf offering of up to $900 million. read more...
Zolmax
2 months ago
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE Get Rating) has been given an average rating of Moderate Buy by the eight brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy ...
TheStreet.com - Investing
3 months ago
In drug development, cash is king, especially during a market correction.In drug development, cash is king, especially during a market correction.If you think tech stocks have it rough right now, sneak a peek at biotech stocks. The sector is in the midst of its most severe correction ever. ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$28.31
$-1.33
(-4.49%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00